2017 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM

2 2017 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM

On behalf of Merck & Co., and the Ernest Mario School of Pharmacy at Rutgers University, thank you for expressing your interest in the Pharmaceutical Industry Fellowship Program. As you move forward in your career, I encourage you to consider the fellowship opportunities at Merck.

Led by former fellows and senior members of the management team, Merck Research Laboratories (MRL) and Global Human Health (GHH) have designed two-year fellowship programs that will offer you a tremendous opportunity to learn, grow, and be part of a dynamic and exciting culture in the areas of Translational Medicine, Clinical Sciences and Study Management, Clinical Safety & Risk Management, Global Regulatory Affairs, Global Medical Affairs, and Quantitative Pharmacology and Pharmacometrics (QP2). We believe these critical areas in the drug development process offer fellows a unique opportunity to build skills and gain hands-on experience that will be invaluable as they pursue a rewarding career in the pharmaceutical industry.

We have a strong commitment to continually develop a program that can generate success for you, Rutgers University, and Merck. We recognize that you are among the best and the brightest coming out of pharmacy school, bringing a strong track record of high achievement. Our program is designed to allow you to continue your success in a post-doctoral environment and for us to work with and train the potential leaders of tomorrow.

The fellowship program at Merck is occurring at an exciting time as we have the most powerful R&D engine in our company’s history. Merck is a strong and diverse company with an extensive global reach. We have a broad pipeline, a number of products to help people, and we are more passionate than ever about what matters most to our customers and the patients we serve.

At Merck, we see every employee as both a team member and a potential leader with the power to influence others through his or her actions. Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity, and teamwork of our employees. This fellowship program is a component of our organizational focus on people.

As many of you will learn from the Merck fellowship leadership team during your interviews, we all take great pride in our work and our business of improving human health. We have an excellent program, and we’re looking for exceptional candidates to become a part of that program. I wish you the best of luck during the recruitment process and hope you will strongly consider the unique fellowship opportunities at Merck.

With Best Regards,

Roy D. Baynes, M.D., Ph.D.

A MESSAGE FROM THE SENIOR VICE PRESIDENT OF GLOBAL CLINICAL DEVELOPMENT & CHIEF MEDICAL OFFICER, MRL

3

MRL Fellows 2016-2017

GHH Fellows 2016-2017


CORPORATE OVERVIEW

Who We Are

Merck’s core values are driven by a desire to improve human life, achieve scientific excellence, operate with the highest standards of integrity, expand access to our products, and employ a diverse workforce that values collaboration. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.

Merck has a long and rich history of working to improve people’s health and well being. Through the years, our researchers have helped to find new ways to treat and prevent illness – from the discovery of vitamin B1, to well-known childhood vaccines, to cold remedies and antacids, to treatments for life-threatening diseases such as oncology and HIV. Our scientists also have helped develop many products to improve animal health, including vaccines and antibiotics.

While we are proud of our past, we are enthusiastic about the future of this company and we are excited to help create a healthier, brighter future for people around the world.

How We Operate

Our goal is to lead the way to a healthier future, but we also care about how we get there together. As a company whose products touch the lives and well-being of people around the world, we hold ourselves to a high standard, and we expect others to hold us to that same high standard. We believe in operating openly, honestly, and with the highest degree of ethics and integrity. We also value the diverse contributions of our employees around the world, and are committed to creating a workplace that is open, welcome, and respectful of all of our employees. These values and principles are at the heart of who we are as a company.

““ We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. How can we bring the best of medicine to each and every person? We cannot rest until the way has been found with our help to bring our finest achievements to everyone.

George W. Merck

5

MERCK PRODUCT PAGECurrently Promoted Products:


ABOUT THE PROGRAM

Program History

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 19 companies within the pharmaceutical and biopharmaceutical industries and over 160 fellows annually.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the Institute for Pharmaceutical Industry Fellowships to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

• Provide leadership and administrative support;

• Promote quality, communication, and scholarly activity; and

• Arrange specialized fellowship training opportunities within the pharmaceutical and biopharmaceutical industries.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor II of the Ernest Mario School of Pharmacy and Dr. Michael Toscani, Research Professor and the Fellowship Director for the Institute for Pharmaceutical Industry Fellowships.

More than 850 post-doctoral fellows have completed the RPIF Program, most of whom are pursuing influential and rewarding careers in the pharmaceutical and biopharmaceutical industries throughout the US and abroad. The RPIF Program has preceptors/mentors from industry who share their knowledge and experiences with the fellows through an intense but closely-guided training program. Assignments and

projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industries and the fellow’s functional area.

Professional Development Series

All fellows gather at Rutgers once or twice monthly as a group to participate in the Professional Development Day (PDD) Series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of fellows and are designed to enhance the fellows’ presentation skills, emotional intelligence, promote connectivity and a sense of community among fellows from different companies and disciplines, develop new skill sets under the guidance of external trainers, and provide general knowledge about various aspects of drug development and issues facing the pharmaceutical and biopharmaceutical industries.

The fellows learn from each other through individual and group presentations and debates on topics and issues related to the pharmaceutical and biopharmaceutical industries. This dynamic forum provides an opportunity for open discussion and debate among fellows, Rutgers faculty, and company preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success; professional writing, presentations, meeting facilitation, negotiating, influencing, networking, and conflict resolution skills; giving and receiving feedback; and business and dining etiquette). Other PDD guest speakers include senior industry executives, patient advocacy groups, and successful RPIF Program alumni who share their insights and experiences. Importantly, PDDs provide an excellent opportunity for fellows to interact with each other and develop lasting personal friendships and a strong professional network of fellows, faculty, alumni, and other industry executives.

Michael Toscani, PharmD Research Professor, Fellowship Director,

Institute for Pharmaceutical Industry Fellowships

Joseph A. Barone PharmD, FCCP

Dean and Professor II Ernest Mario School of Pharmacy

7

Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program FOSTERs the growth and development of future pharmaceutical and biopharmaceutical industry professionals through the following key program features:

Rutgers, The State University of New Jersey, with approximately 65,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is the only state school of pharmacy in New Jersey, with approximately 1,400 students in its Doctor of Pharmacy program.

The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with exposure to the pharmaceutical and biopharmaceutical industries.

F amily of Leading

Companies–Partners include several of the top 19 global pharmaceutical and biopharmaceutical companies.

Outstanding Alumni

Track Record–Over 850 alumni hold prominent positions at many leading companies.

S trong Network—

Over 160 fellows each year develop valuable, lasting connections with each other, alumni, preceptors and faculty.

T he Pathway to Industry–

Since 1984, the Rutgers program has been nationally recognized, trusted, and proven as the pathway to industry for pharmacists.

E nhanced Career

Path–Increasingly challenging assignments build depth of experience and enhance the potential for an accelerated career path.

R igorous Academic

Component–Rutgers affiliation provides academic and professional development opportunities.


Within the Department of Translational Medicine (TM), the Translational Pharmacology (TPharm) group is responsible for the conduct of clinical trials. TPharm conducts the global clinical evaluation of the safety, pharmacokinetics, and pharmacodynamics of molecular and biological therapeutics in healthy subjects and selected patient populations within the regulatory requirements for new investigational products. The TPharm group includes the following divisions: TPharm Therapeutic Areas, Clinical Pharmacology, TPharm Clinical Operations (TPCO) and EU Operations.

The TPharm Therapeutic Areas are aligned with the Discovery Organization and include Cardiovascular and Metabolic Diseases, Neurology, and Infectious Disease/Vaccines/Inflammation. The mission of this group is to discover new targets and biomarkers based on causal human biology, design and conduct first in human (FIH) and clinical proof of concept (POC) studies, and build novel clinical platforms to test therapeutic hypothesis. TPharm conducts trials to support general clinical pharmacology and programs in late development. TPCO provides efficient operations support for all clinical trials within TM, and the EU Operations group conducts non-US trials to advance compounds and establish safety and clinical POC. As a whole, TPharm provides all the preliminary safety, pharmacokinetic, and pharmacodynamics scientific support for the progression into late stage clinical studies in patients across all MRL therapeutic areas.

Within TPCO, the Early Clinical Scientist (ECS) fellow will be responsible for developing protocols, developing case report forms for data collection, initiating studies, data monitoring, data clean-up, and reporting of studies. The focus of the investigations will be geared toward the understanding of new molecular entity (NME) safety and tolerability in healthy subjects and patients, mechanism of action pharmacokinetics, pharmacodynamics, as well as proof of concept.

The ECS fellow will be a member of Study Teams and working groups where they will collaborate with other functional area representatives including Pharmacokinetics, Statistics, Data Management, Clinical Supplies, and Regulatory Affairs.

MERCK COMPONENT:TRANSLATIONAL MEDICINE

Preceptor: Evan Friedman, MS Principal Scientist, Clinical Research,

Translational Medicine

Preceptor: Matt Anderson, PhD

Senior Principal Scientist,Clinical Research,


Second Year Fellow: Mengsong LiPharmD, RPh


First Year Fellow: Kezia Gravesande

PharmDTranslational Medicine

9

QUANTITATIVE PHARMACOLOGY AND PHARMACOMETRICS

Within the Department of Pharmacokinetics (PK), Pharmacodynamics (PD) and Drug Metabolism (PPDM), the Quantitative Pharmacology and Pharmacometrics (QP2) group is responsible for developing and executing PK/PD and Modeling and Simulation (M&S) strategies and applying functional area knowledge to frame critical drug development questions for optimizing model-based drug development as a member of cross-functional drug development teams. QP2 scientists apply PK/PD and M&S approaches to design and evaluate clinical and preclinical study data, characterize the kinetics of drug absorption and disposition, assess the dynamics of drug effect, and inform dose selection and go/no-go decisions. Our scientists also maintain a comprehensive understanding of global regulatory expectations for small molecules and biologics, including authoring regulatory documents (INDs, CSRs, CTDs) and representing the department at regulatory meetings. The QP2 scientist is a quantitative drug developer with a strong, integrated understanding of the strategic elements of drug development (early through late) and leads the combined efforts of QP2 & the wider PPDM department, applying these methodologies across each of the therapeutic areas.

In addition, QP2 scientists demonstrate outstanding leadership, communication, and collaboration with key functional areas to create an aligned, quantitative framework for impactful decision making on drug development teams. This is accomplished in several key scientific areas for QP2, including translational and clinical PK/PD analyses, clinical trial simulations, disease state modeling, clinical outcomes modeling, comparator modeling, absorption/biopharmaceutical modeling, adaptive design, clinical utility indices, translation of biomarkers to clinical outcomes, enrollment modeling, etc.

The QP2 fellow will be responsible for developing expertise in PK/PD and M&S through efforts designed to support the antibacterial therapeutic area. These efforts will focus on translational sciences designed to provide input on the design of in vitro and preclinical experiments, quantitatively analyze the resulting data, and integrate the results with PK and PD data from clinical studies. Together, the results of these analyses will be publishable and will have direct impact on programs in Merck’s antibacterial portfolio, influencing dose selection, breakpoint determination, the influence of demographic factors on dose, the prediction of clinical efficacy, and other key decisions.

Through involvement and interaction with other functional areas, the fellow will also become familiar with the application of PK/PD and M&S in other therapeutic areas, microbiology and epidemiology, clinical pharmacology and clinical research, regulatory policy, and scientific leader engagement in the antibacterial field.

Preceptor: Matthew Rizk, PhD

DirectorQP2

“During my time with Merck as a fellow,

I had the opportunity to work with

many different innovative, talented, and

passionate mentors. With their support,

I was able to build the necessary skill

sets to be successful in my area, while

continuing to expand on my leadership

capacities and knowledge in the

pharmaceutical sciences.”

– Daniel Jonathan, PharmD RPIF Merck Fellowship

Class of 2012-2014 Translational Medicine


First Year Fellow:Saba Emami

PharmDCSSM

Second Year Fellow: Suneri Shah PharmD, RPh

CSSM

Preceptor: Yanfen Guan, MS

Associate Principal Scientist CSSM

Global Clinical Trial Operations (GCTO) supports Merck’s Mission to discover, develop, and provide innovative products and services that save and improve lives around the world.

Clinical Sciences & Study Management (CSSM) is a sub-functional unit within GCTO accountable for all operational, technical, and scientific aspects of headquarters-sponsored clinical trials, including local registration trials and regulatory commitments. The Clinical Scientist (CS)/Study Manager (SM) fellow will support the scientific aspects of late stage clinical development within therapeutic areas of oncology, diabetes, or respiratory & immunology, as well as play a key role in the operational planning and execution activities for our LSD clinical studies.

Through involvement and interaction with other functional areas, the fellow will become familiar with patient recruitment, patient retention, protocol design, scientific and operational oversight of trials, and more. The fellow will have an opportunity to serve as a member of a Clinical Trial Team (CTT) or Outsourced Trial Team (OTT) and collaborate with other functional areas including Clinical Directors, Statistics, Regulatory Affairs, Therapeutic Area Document Review Committees, Data Management, Clinical Supplies, and Regional Clinical Operations. The principal goals of the Fellowship will be to provide an overview of the functional role of the CS/SM in the drug development process, and training opportunities aligned with the role of the CS/SM at Merck.

The fellow has the opportunity to be involved with study start-up, conduct, or closeout activities. Some of these activities include: program planning and management, study planning and management, CTT leadership, protocol/amendment authoring, case report form development, budget management, protocol feasibility, country selection, patient enrollment projections, medical monitoring of clinical data, trial tracking and reporting, program and study communication, and final study report authoring.

Whether fellows focus their training in early or late phase clinical research, they will also gain an understanding of Good Clinical Practices, as well as requirements for Investigational New Drug (IND) and New Drug Application (NDA) submissions.

LATE STAGE DEVELOPMENT

Preceptor: Sandria De Sapio

Associate Principal Study Manager

CSSM

11

GLOBAL REGULATORY AFFAIRS

As part of Merck’s Global Regulatory Affairs and Clinical Safety (GRACS) group, Regulatory Affairs proactively provides regulatory expertise and strategic guidance in all aspects of the drug development process in order to ensure the production of quality submissions that meet Health Authority requirements and allow for expeditious review and approvals. Regulatory Affairs is also responsible for maintaining marketed products in compliance with regulatory requirements.

The focus of the two-year fellowship is in the Worldwide Regulatory Group (WRG) within GRACS. This group is responsible for providing regulatory strategic input in the design of preclinical and clinical development programs for all Merck pharmaceutical products (including in-licensed products). The fellow can rotate between therapeutic areas in order to experience and support key strategic regulatory milestones. The goal of the WRG fellowship is to prepare the fellow for a career in clinical/therapeutic regulatory affairs in the pharmaceutical industry. This will be done through a rigorous, hands-on training program that exposes the fellow to the various aspects of global regulatory affairs in an industry setting.

Under the direction of a Director in WRG, the fellow will act as a member of cross-functional project teams and gain experience in the development of global regulatory strategic plans, filing and/or strategic development of regulatory dossiers, and routine and complex requests from Health Authorities, and will provide regulatory intelligence and lead regulatory aspects of development milestones. The fellow will ensure that the content, organization, and quality of all regulatory documentation (i.e., INDs/IDDs, NDAs/MAAs, supplements, variations, and responses to questions and comments) are in compliance with local and/or regional regulatory requirements and commitments. The fellow will

have the opportunity to interact with other departments within Merck, such as Clinical Research, CMC Regulatory (Chemistry, Manufacturing and Controls), and Safety to learn how global regulatory affairs is incorporated throughout the organization.

The fellow and other members of the WRG are responsible for directing internal and external activities aimed at meeting regulatory requirements. As necessary, the fellow along with Merck subject matter experts, including regulatory, may interact with the U.S. FDA and international regulatory agencies to discuss and agree on issues relating to development programs and/or responses to Health Authority questions. All representatives of the WRG also liaise with other Merck regulatory personnel around the world.

Preceptor: Melissa Tice, PhD

Dist. Scientist Regulatory Liaison,

WRG - Oncology, Immunology, Biologics & Devices

“Completing a 2-year Regulatory

Affairs Fellowship established a

strong foundation for my career. My

experiences opened my eyes to the

many challenges in drug development

and the unique opportunities for

pharmacists to be able to contribute

to the pharmaceutical industry.”

– Ripal Shah, PharmD RPIF Merck Fellowship

Class of 2007-2009 Global Regulatory Affairs

First Year Fellow: Andro Shenouda

PharmD, MSGlobal Regulatory Affairs

First Year Fellow: Basirat Adeyemi

PharmDGlobal Regulatory Affairs


Within the Global Regulatory Affairs and Clinical Safety (GRACS) group, the mission is to improve public health by assuring the safe use of Merck products worldwide through proactive safety assessment, effective risk management, and transparent risk communication throughout the developmental and marketed product lifecycle. We are offering a two-year fellowship in Clinical Safety & Risk Management (CSRM) with the opportunity to receive significant training and experience in the many aspects of clinical safety and risk management.

The goal of the CSRM fellowship is to prepare the fellow for a career in pharmacovigilance and risk management in the pharmaceutical industry. This will be done through a rigorous, hands-on training program that exposes the fellow to the various aspects of global product safety in an industry setting.

Under the general direction and mentoring of a CSRM Director, the fellow will develop expertise in, and gradually assume greater responsibility for, the overall clinical risk management and safety surveillance of assigned marketed products. The fellow will learn about all aspects of safety surveillance, including assessing safety information, safety signaling, and data mining, along with ensuring completeness of that safety information in worldwide package circulars. The fellow will have joint responsibility for the development of periodic safety update reports and risk management plans and will partner with appropriate Merck departments and therapeutic areas to ensure efforts are aligned to meet our global risk management strategies for assigned products. The fellowship will also involve working with the CSRM group to help develop processes for the improved functioning of the fellowship program, and implement specific initiatives to achieve identified goals.

The fellow will have the opportunity to interact with other departments within Merck, such as Medical Affairs, Epidemiology, Clinical Research, Biostatistics, and Regulatory Affairs to learn how Clinical Safety & Risk Management is incorporated throughout the organization. Additionally, the fellow will learn how pharmaceutical manufacturers use data to support research, development, approval, and access for new therapeutic products.

CLINICAL SAFETY & RISK MANAGEMENT

Preceptor: Suzanne Skarzynski, PharmD

Director CSRM

Second Year Fellow: Solomon Hassanzadeh

PharmD CSRM

“The Post-Doctoral Fellowship Program

at Merck provided me with the tools

and skills needed to jump-start

my career in the pharmaceutical

industry. The challenging and

rewarding experiences accelerated

my professional development.”

– Mujtaba Shahsamand, PharmD RPIF Merck Fellowship

Class of 2012-2014 Clinical Safety & Risk Management

First Year Fellow: Victoria Lopomo

PharmD, RPhCSRM

13

GLOBAL MEDICAL AFFAIRS: GLOBAL MEDICAL INFORMATION/ONCOLOGY GMA

Global Medical Affairs (GMA), which falls under the Global Human Health (GHH) Division, serves as a strategic partner to the franchises and regions, providing high-quality medical expertise to the business and to our customers. GMA helps to meet the needs of healthcare professionals and organizations by generating and communicating information that helps them make informed choices that improve health outcomes for patients.

Global Medical Information (GMI) is part of Global Medical Affairs. GMI includes a diverse group of scientists and healthcare professionals.

The mission of GMI is to:

• Author medical content that is leveraged globally and provide accurate and timely medical information to unsolicited requests from healthcare professionals, hospitals, and managed care organizations

• Provide medically accurate review/approval of US and Global advertising and promotional materials created by marketing, training, and managed care

• Develop/deliver medical assets for product and disease training

• Support launch activities around the globe

GMI interacts cross-functionally with many departments, including the Office of Promotion Advertising & Review (OPAR), Regulatory Affairs, Learning and Development, Global Safety, Clinical Research, Legal, Compliance, Global Quality, the Merck Manufacturing Division, and US and Global Marketing. GMI also facilitates medical expert engagement, including educational grants and US and Global Advisory Boards.

Fellows in this Merck Rutgers program will have a broad experience across the GMA organization. During their first year, fellows will work in GMI on the Oncology Therapeutic Area Team. Fellows will become familiar with unsolicited

Professional Information Requests (PIRs) and learn how fair-balanced and accurate responses are developed and sent to customers. They will gain experience in the medical review of promotional materials for marketed products, learn how training materials are developed/delivered, and become involved in launch activities around the globe.

During the second year of the Fellowship, there will be an opportunity for Fellows to work with Oncology Global Medical Affairs (OGMA), which is part of the Oncology Customer Business Line in GHH. The vision of Merck Oncology is to deliver breakthrough innovations to extend and improve the lives of people with cancer. OGMA is made up of oncology experts who maximize value by engaging with the oncology community, providing them with critical, beneficial, and balanced data to inform life and death decisions.

The Fellows will have the opportunity to work on specific operational projects within the OGMA Team, create Oncology resources that are shared with Scientific Leaders, and support the Oncology community alongside the Oncology Medical Science Liaisons.

Preceptor: Anne Flanigan-Minnick, PhD

Director Global Medical Affairs

Second Year Fellow: Allison Doherty PharmD, RPh

Global Medical Affairs

Second Year Fellow: Irene Okeke

PharmD, RPh Global Medical Affairs

First Year Fellow: Julian Kam

PharmDGlobal Medical Affairs

First Year Fellow: Lindsey Sosnowski

PharmDGlobal Medical Affairs

Preceptor: Rebecca Lakata, RN, MSN

Oncology Global Medical Affairs

Chief of Staff


The mission of US Medical Affairs (USMA) is to serve population health by rapidly translating the totality of evidence into relevant health care solutions. USMA accomplishes this mission by partnering with internal and external stakeholders to communicate relevant information, which enables appropriate, accurate, and timely access to relevant Merck science and therapies. USMA Fellows will have broad experiences across the USMA organization by rotating through the following functions in the USMA organization, across a range of therapeutic areas including cardiovascular and metabolic disease, neuroscience, virology, infectious disease, anesthesia/surgery, oncology, and vaccines:

Field Medical function: Field Medical colleagues are therapeutic and disease experts, who represent Merck to the external medical and scientific community. Those focused on specific therapeutic areas develop ongoing professional relationships with a range of scientific leaders (health care providers-HCPs), while Health Systems colleagues provide cross-therapeutic support to health system decision makers within payer and provider organizations across the country. The Fellow will have significant opportunity during the field medical rotation to engage in scientific and medical discussions with scientific leaders (HCPs) and key decision makers.

Therapeutic and Customer Segment Strategy: The US Medical Affairs Strategy Leads (MASLs) provide expert scientific and medical advice to Merck for each therapeutic or functional area to support the development of appropriate medical affairs strategies. MASLs maintain internal relationships with internal stakeholders to ensure strategic alignment of medical affairs activities. MASLs also engage with external scientific leaders and key decision makers to obtain inputs that inform the Medical Affairs strategy. During the strategy rotation, working closely with MASLs, the Fellow will participate in the input gathering and strategic decision process.

Content and Training: The US Medical Affairs Content Directors collaborate with the MASLs in content development to provide the Field Medical colleagues with approved resources for medical and scientific training and for use in engagements with external scientific leaders and key decision makers. In the content rotation, the Fellow will work under the guidance of Medical Affairs Content Directors to create medical and scientific content to enable external engagement by field medical colleagues. The Fellow will take new content through the process of development, review and approval, and training and implementation.

Strategy & Operations: The Strategy and Operations team is staffed by Project Managers who work across functional areas within Merck to drive the project management of new and existing efforts aligned to the medical affairs strategies. The role involves the development and execution of project plans and the identification and creation of needed resources in alignment with applicable policies, in collaboration with Medical Affairs Strategy Leads and Content and Training Directors. The Fellow will have opportunity to execute cross-functional projects required to achieve USMA organizational objectives.

Advocacy and Professional Affairs: The Advocacy and Professional Affairs (APA) managers establish and maintain high quality relationships with professional societies to support educational efforts. Through the grants process, APA enables the delivery of high quality education across the continuum of health care providers. The APA team is engaged in interactions with over two hundred advocacy groups, professional medical societies, seventy pharmacy societies, and the leadership of these organizations. The USMA Fellow rotating through APA will learn and participate in these engagements with professional organizations. The Fellow will attend conferences that are supported by Merck through the APA processes.

GLOBAL MEDICAL AFFAIRS: U.S. MEDICAL AFFAIRS

Preceptor: Everest Nwakamma, PharmD,

MBAProject Manager

U.S. Medical Affairs

The RPIF program is more than just

work experience in pharmaceutical

industry; the teaching, leadership,

and outreach opportunities allow

us to develop our soft skills on top

of valuable on-the-job experience.

I enjoyed my fellowship and the

opportunity to transition into a role

in Global Medical Information and

Operations here at Merck.

– Kim Le, PharmD RPIF Fellowship

Class of 2013–2015 Medical AffairsPreceptor:

Stephen DodgePharmD, MBA

Executive Director U.S. Medical Affairs

First Year Fellow: Sandeep Balabbigari

PharmD U.S. Medical Affairs

15

Ernest Mario School of Pharmacy, Piscataway, NJ

Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally-competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE accredited institution before July 1 of the fellowship term.

Participation in the ASHP Midyear Clinical Meeting/PPS is strongly encouraged. Interested individuals are invited to electronically submit a curriculum vitae, three letters

of recommendation and a letter of intent and complete a program interest form online by visiting our website at:

Joseph A. Barone, PharmD, FCCP Dean and Professor II Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey 160 Frelinghuysen Road Piscataway, NJ 08854-8020 [email protected]

APPLICATION PROCESS AND ELIGIBILITY REQUIREMENTS

EXECUTIVE SPONSORS AND DIRECTORS

Gowri Murthy, PharmD, MBAPrincipal Scientist

Translational MedicineProgram Alumna

Eric Rubin, MDExecutive Sponsor

Vice PresidentClinical Research

Oncology Early Development

Jill DeSimoneExecutive Sponsor

Senior Vice President,US Oncology

Commercial Operations

Ken Massey, PharmDUSMA SponsorVice President

US Medical Affairs

Sauzanne Khalilieh, PharmDFellowship Director

Sr. Principal Scientist Translational Pharmacology

Program Alumna

Ripal Shah, PharmDFellowship DirectorRegulatory Liaison

Worldwide Regulatory GroupProgram Alumna

Application materials may be submitted as early as November 19, and applicants are encouraged to submit as many of the required materials as possible by December 15.


Rutgers, The State University of New Jersey, with approximately 65,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is the only state school of pharmacy in New Jersey, with approximately 1,400 students in its Doctor of Pharmacy program.

The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with exposure to the pharmaceutical and biopharmaceutical industries.

RUTGERS UNIVERSITY AND THE SCHOOL OF PHARMACY

Paterson

Newark

Asbury Park

RutgersUniversity

Trenton

Philadelphia

Atlantic City

Kenilworth Rahway

Upper Gwynedd

NYC

PA NJ

17

Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, NJ 07033 908.423.1000

www.merck.com

Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey 160 Frelinghuysen Road Piscataway, NJ 08854-8020

The trademarks indicated by CAPITAL LETTERS in this publication are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies, except as noted. As used in this publication, the terms “Merck” and the “Company” refer collectively to Merck & Co., Inc., the publicly held parent company, and its domestic and international subsidiaries, which are engaged in the discovery, development, manufacturing and marketing of pharmaceutical and animal health products.

Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved.

2017 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM · interest in the Pharmaceutical Industry...

Documents

Transcript of 2017 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM · interest in the Pharmaceutical Industry...